Akebia Therapeutics to Present at Canaccord Genuity’s 45th Annual Growth Conference
Rhea-AI Summary
Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focused on kidney disease treatments, has announced its participation in Canaccord Genuity's 45th Annual Growth Conference. The company's CEO, John P. Butler, will engage in a Fireside Chat on Wednesday, August 13 at 1:30 PM EDT.
The conference is scheduled for August 12-14, 2025 in Boston. Investors can access the presentation webcast through the Investors section of Akebia's website after the conference.
Positive
- None.
Negative
- None.
CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, will participate in a Fireside Chat at Canaccord Genuity’s 45th Annual Growth Conference on Wednesday, August 13 at 1:30 PM EDT. The conference will take place August 12-14, 2025 in Boston.
A webcast of the presentation can be accessed through the “Investors” section of Akebia’s website at https://ir.akebia.com following the conference.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
FAQ
When is Akebia Therapeutics (AKBA) presenting at the Canaccord Genuity Growth Conference 2025?
How can investors access Akebia Therapeutics' (AKBA) Canaccord conference presentation?
Who will represent Akebia Therapeutics (AKBA) at the Canaccord Genuity Conference?
What type of presentation will Akebia Therapeutics (AKBA) give at the Canaccord conference?
